Status:
NOT_YET_RECRUITING
The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
Lead Sponsor:
Peking University People's Hospital
Conditions:
CLL
Eligibility:
All Genders
18+ years
Brief Summary
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
Eligibility Criteria
Inclusion
- 1\. Patients aged ≥18 years old
- 2\. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL \[International Workshop on Chronic Lymphocytic Leukemia\] criteria)；
- 3\. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on Zanubrutinib;
- Prior or current use of Zanubrutinib for ≥3 months
- At least one follow-up was recorded during Zanubrutinib treatment
Exclusion
- \-
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
490 Patients enrolled
Trial Details
Trial ID
NCT06489184
Start Date
August 1 2024
End Date
December 30 2025
Last Update
July 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044